<DOC>
	<DOC>NCT00983853</DOC>
	<brief_summary>The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV and human immunodeficiency virus (HIV).</brief_summary>
	<brief_title>Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic, genotype 1, hepatitis C with detectable HCV RNA HIV1 infection for &gt;6 months Documentation of a liver biopsy within 1 year before the screening visit showing evidence of hepatitis (demonstrated by inflammation and/or fibrosis) Previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C Previous treatment with interferon or ribavirin Evidence of hepatic decompensation in cirrhotic subjects Subjects who have participated in a clinical study involving administration of an investigational drug within 2 months Part A only: subjects who have been on a HAART regimen within 12 weeks before study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>VX-950</keyword>
	<keyword>INCIVEK</keyword>
	<keyword>INCIVO</keyword>
</DOC>